Curis Lifescien. (CURIS)

Score breakdown: P/E: 3/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 75.53% and profit growth of 89.64% show strong earnings momentum.
• ROCE of 34.24% signals efficient use of capital.
• P/E of 9.67 and PEG of 0.12 suggest valuation does not fully reflect growth.
• Promoter holding of 68.03% aligns shareholder interests.
• Piotroski F-Score of 7/9 indicates robust financial-health metrics.

Concerns

• No book value, ROE, or debt-equity data means balance-sheet risk cannot be assessed.
• Zero dividend yield offers no downside cushion for shareholders.
• Small market cap of ₹79 Cr increases volatility and liquidity risk.
• Latest quarter's net profit of ₹4 Cr on ₹28 Cr sales implies thin margins; growth quality needs monitoring.

AI Analysis

When I look at Curis Lifescien, I try to ignore the market's daily mood and ask what the business earns on the money it uses. The figures here are intriguing but incomplete. The company earned a return on capital employed of 34.24%, which is excellent by any standards. A business that can compound capital at those rates deserves study. Sales have grown 75.53% and profits 89.64%; with a PEG of 0.12, the market is paying very little for this growth. At ₹117.90 with a market cap of only ₹79 crore, this is a small enterprise, and a P/E of 9.67 suggests either genuine bargain status or a quality discount. But Graham taught me to demand a margin of safety. Here I am handicapped: book value, return on equity, and debt-to-equity are all unavailable. That prevents me from understanding the balance sheet and whether the reported profits are built on solid net worth or risky leverage. Mr. Market is offering no dividend yield, so the return must come entirely from business performance and eventual re-rating. Promoter holding at 68.03% is positive—it aligns owners with my interests and reduces agency risk. The Piotroski score of 7 out of 9 also indicates healthy operational fundamentals. I would not call this a wide-moat stalwart without knowing its product portfolio and competitive position. It is a fast grower, with the price suggesting an attractive entry, but 'caveat emptor' applies: small market cap, missing data, and thin margins demand careful watch. If the growth sustains, the current price could look very cheap; if not, the lack of a dividend leaves no cushion.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer